Welcome to our dedicated page for Iridex SEC filings (Ticker: IRIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want to know how sales of MicroPulse® laser consoles are trending or whether insiders are buying stock before new clinical data? This Iridex SEC filings hub starts where most ophthalmology investors begin—searching for hard-to-find data hidden in 10-Ks and 10-Qs. From cash flow tied to disposable probe sales to FDA-related 8-K disclosures, every document is organized and tagged so you can stop hunting and start analyzing.
Use Stock Titan’s AI to move straight to answers. Our algorithms deliver Iridex SEC filings explained simply: instant highlights of revenue by product line, flags on R&D spending changes, and side-by-side Iridex earnings report filing analysis. Need quick transaction intel? Receive Iridex Form 4 insider transactions real-time alerts that clarify Iridex executive stock transactions Form 4 in plain language. Each link opens the original EDGAR text plus an AI summary that answers common queries like “How did gross margin shift this quarter?” or “Which directors exercised options?”
- 10-K: The Iridex annual report 10-K simplified pinpoints consumable vs. console revenue and global distributor performance.
- 10-Q: Read the latest Iridex quarterly earnings report 10-Q filing with AI-generated trend notes.
- Form 4: Track Iridex insider trading Form 4 transactions moments after they post.
- 8-K: Critical announcements—Iridex 8-K material events explained without jargon.
- DEF 14A: The Iridex proxy statement executive compensation section highlights incentive alignment with glaucoma therapy milestones.
Whether you’re understanding Iridex SEC documents with AI for the first time or comparing quarter-over-quarter adoption of retina lasers, our real-time feed and concise commentary turn dense filings into actionable insights.
Iridex Corp (IRIX) Form 4: The reporting person, Romeo R. Dizon (CFO), made a purchase of 625 shares of Iridex common stock on 08/29/2025 at a price of $1.37 per share. Following the transaction, Mr. Dizon beneficially owned 52,375 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Romeo R. Dizon, Chief Financial Officer of Iridex Corp (IRIX), reported multiple open-market purchases totaling 1,005 shares on 08/28/2025. The transactions executed at prices between $1.325 and $1.36 per share increased his direct beneficial ownership from 50,745 shares to 51,750 shares. Individual purchases reported: 50 shares at $1.33, 200 shares at $1.325, 250 shares at $1.35 and 505 shares at $1.36. The Form 4 was signed by an attorney-in-fact on 08/29/2025. No derivative transactions were reported and no additional explanatory text was provided.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported purchases of common stock on 08/27/2025. The filing shows three open-market acquisitions totaling 1,000 shares: 500 shares at $1.28, 250 shares at $1.2746, and 250 shares at $1.2964. Each line reports the resulting beneficial ownership rising sequentially to 50,245; 50,495; and 50,745 shares, and ownership is reported as direct. No derivative transactions were reported. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.
Iridex Corp Chief Financial Officer Romeo R. Dizon reported purchases of common stock on 08/26/2025. The filing shows two open-market buys: 750 shares at $1.26 and 250 shares at $1.25, for a total of 1,000 shares acquired. Following these transactions his beneficial ownership increased to 49,745 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and contains no derivative transactions or additional explanatory notes.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported four separate purchases of common stock on 08/25/2025. Each transaction (code P) was for 250 shares at prices of $1.25, $1.245, $1.24 and $1.2454, increasing his reported beneficial ownership sequentially to 47,995, 48,245, 48,495 and 48,745 shares. The Form 4 was signed by an attorney-in-fact on 08/26/2025.
Insider purchases increased stake in IRIDEX Corp. Romeo R. Dizon, the company's Chief Financial Officer, acquired a total of 1,000 shares of IRIDEX common stock on 08/22/2025 in three open-market transactions priced at $1.21, $1.22 and $1.23 per share. Following these purchases his reported beneficial ownership rose from 46,995 to 47,745 shares. The Form 4 was signed by an attorney-in-fact on 08/25/2025.
Iridex Corp (IRIX) Form 4: Chief Financial Officer Romeo Dizon reported two purchases on 08/21/2025 totaling 2,000 shares of common stock. The first purchase was 1,000 shares at $1.27 and the second was 1,000 shares at $1.22. Beneficial ownership increased to 46,745 shares following the transactions. The form was signed 08/22/2025 by an attorney-in-fact.
Romeo R. Dizon, Chief Financial Officer of IRIDEX Corp (IRIX), reported two open-market purchases on 08/20/2025. He acquired 825 shares at $1.17 and 175 shares at $1.25, bringing his reported beneficial ownership to 44,745 shares following the transactions. The Form 4 was signed by an attorney-in-fact on 08/21/2025.
The filing lists Mr. Dizon's address in Mountain View, CA, and indicates the report was filed by one reporting person. No derivative transactions or additional explanations were provided in the filing.
Iridex Corp (IRIX) reported insider purchases by Chief Financial Officer Romeo R. Dizon on 08/19/2025. The reporting person acquired a total of 1,500 shares through three purchase transactions: 1,000 shares at $1.18, 500 shares at $1.16, and an aggregate line showing 1,500 shares at $1.1593, bringing his direct holdings to 43,745 shares after the trades. The Form 4 was signed by an attorney-in-fact on 08/20/2025.
William M. Moore, a director of Iridex Corporation (IRIX), reported purchases of the company’s common stock on 08/18/2025. The filing shows he acquired 12,024 shares at a weighted average price of $1.1834 per share (prices ranged from $1.175 to $1.1899). After the purchases, Mr. Moore directly beneficially owned 200,674 shares. The filing also discloses indirect holdings of 69,300 shares held by his spouse and 30,026 shares held in two trusts where he and his spouse serve as trustees/tenants in common. The Form 4 was signed on behalf of Mr. Moore by an attorney-in-fact on 08/19/2025.
FAQ
What is the current stock price of Iridex (IRIX)?
What is the market cap of Iridex (IRIX)?
